how do doctors want to engage with pharma on new … · 2016-06-14 · how do doctors want to...
Post on 19-Jun-2020
8 Views
Preview:
TRANSCRIPT
HOW DO DOCTORS WANT TO ENGAGE WITH PHARMA ON NEW PRODUCTS?dr tim ringrose, Ceo, M3 (eu)DECEMBER 2014
More than 80% of European doctors say they want to stay abreast of new developments about pharmaceutical products. But how do they want to receive this information?”
“
”IN ASSOCIATION WITH
01 Introduction
02 What most influences doctors’ choice of treatment?
04 How doctors like to receive promotional material
05 Preferred sources and formats when researching pharma products
06 How doctors spend their professional time online
07 Attitudes to online learning and conclusions
08 Information on M3 Group
Contents
01 How do doctors want to engage with pharma on new products?
“72% of EU doctors say pharma’s delivery of new medicines will be the main factor contributing to improving the outlook for their patients over the next three years”
IntroduCtIon
new data from M3 Global research shows eu doctors are optimistic about pharma’s ability to deliver new medicines, with 72% of them saying they are key to improving the outlook for their patients over the next three years (Figure 1).
Indeed, new medicines are considered more influential than ‘better management of
chronic conditions’ and ‘more patient education’, which were respondents’ second
and third top choices respectively.
In line with this, more than 80% of european doctors agree they are interested in
staying up-to-date with new developments about pharmaceutical products. But
what influences their choice of treatment and how do they prefer to receive product
information?
M3 Global research put these questions to 1,848 eu doctors mainly from the top
five eu nations – Germany (332); France (380); Italy (266); spain (293) and uK (318).
We hope that their answers will prove useful to pharma marketers when deciding how
best to engage with doctors in the eu.
New drugs/treatments available
All EU (1848)
72%
0% 50% 100%
Germany (332)
France (380)
Italy (266)
Spain (293)
UK (318)
Better management of chronic conditions
More patient education
New treatment for terminal conditions
Availability of generics
78%71%
73%76%
62%
45%27%
55%49%
45%56%
38%19%
45%39%
46%46%
26%31%
37%17%18%
15%
13%16%
9%10%
9%21%
Figure 1: Reasons for significant improvement in outlook
02 How do doctors want to engage with pharma on new products?
Healthcare spending throughout europe is highly politicised, coming as it does from an increasingly constrained public purse. national efforts to limit either the supply of, or demand for, medicines go some way therefore to explaining the marked differences in how doctors from the largest eu nations identify the three top influences on their choice of treatments.
Guidelines would seem to be the most pertinent influence in the uK. Figure 2 shows
that national guidelines (for example, those published by the uK’s national Institute
for Health and Care excellence) were mentioned by 69% of uK doctors and local
guidelines and availability on formulary by 56%. In contrast, national guidelines were
only mentioned by 30% of spanish doctors and local guidelines by as few as 5% of
French doctors and 21% across the eu.
the influence of guidelines on treatment decisions is highlighted in Figure 2a, which
shows the respective scores from the five major eu countries.
WHAt Most InFluenCes doCtors’ CHoICe oF treAtMent?
Figure 2a: Influence of guidelines on medical treatment
Clinical papers/evidence
National guidelines(e.g. NICE)
International guidelines
Medical education
Symposia/conferences
Local guidelines/formulary
Price of treatment
All EU (1848)
Germany (332)
France (380)
Italy (266)
Spain (293)
UK (318)
54%46%
65%58%
57%39%
44%46%
44%36%
30%69%
43%45%
31%70%
46%14%
39%36%
37%43%
63%27%
26%39%
37%17%
16%10%
21%18%
5%17%
15%56%
20%25%
18%16%
17%25%
0% 20% 40% 60% 80%
International guidelines National guidelines Local guidelines
43%
45%
31%
70%
46%
14%
44% 21%
46% 18%
44% 5%
36% 17%
30% 15%
69% 56%
All EU (1848)
Germany (332)
France (380)
Italy (266)
Spain (293)
UK (318)
Figure 2: Influences on medical treatment
How do doctors want to engage with pharma on new products? 03
europe is also host to various medical traditions and cultures, which may explain why
international guidelines are so much more influential in treatment decisions in Italy,
cited by 70% of respondents, in contrast to the uK’s 14%. It may also explain why
medical education resonates so widely among spanish doctors with 63% citing it as a
leading influence in contrast to 27% among their British counterparts.
overall, the picture is highly variable with the most consistent influence being the
evidence presented in clinical papers. But even within this single leading factor, there
are marked contrasts with 64% of French doctors, for example, citing this at one end
of the spectrum and only 39% of uK doctors at the other.
other sources of influence mentioned but not tabulated in Figure 2 include:
• Promotional information from pharma companies: selected by 4% of
respondents, rising to 8% in spain and Italy and dipping to 3% in the uK and 2%
in Germany.
• Key opinion leaders (Kols): selected by 8% of respondents.
• Peer advocacy / prescribing behaviour: selected by 34% of respondents in
France, 17% in the uK and 12% in spain.
Clinical papers/evidence
National guidelines(e.g. NICE)
International guidelines
Medical education
Symposia/conferences
Local guidelines/formulary
Price of treatment
All EU (1848)
Germany (332)
France (380)
Italy (266)
Spain (293)
UK (318)
54%46%
65%58%
57%39%
44%46%
44%36%
30%69%
43%45%
31%70%
46%14%
39%36%
37%43%
63%27%
26%39%
37%17%
16%10%
21%18%
5%17%
15%56%
20%25%
18%16%
17%25%
0% 20% 40% 60% 80%
“Overall the picture is highly variable with the most consistent influence being the evidence presented in clinical papers”
04 How do doctors want to engage with pharma on new products?
While promotional material from pharma companies is clearly not a top influence in treatment decisions (selected by an average of only 4% of doctors), understanding how eu doctors prefer to receive such material can help boost its impact.
In top place is the face-to-face visit from a sales rep, followed by information
disseminated from an independent website (see Figure 3). For this question, the
respondents were asked for their top three choices (a first scores 3, a second 2, a
third 1 and no points if an option is not chosen at all).
Further analysis, depicted in Figure 3a, shows two options (downloadable content
and emails from independent websites) are closely related with a much higher
preference for independent website contact among doctors who do not see reps. the
researchers looked specifically at how the doctors responded to the option regarding
face-to-face rep visits, filtering out those who selected this as a first choice (569 or
30.8%), as one of three choices (1056 or 57.1%), and as no option (792 or 42.9%).
those who close their doors to the sales force are shown to prefer to visit or receive
communications from independent websites more than the average doctor. For
downloading content, the ‘no reps’ group scored 63% versus a 50% average; for
receiving emails, the figures are 49% versus a 34% average, and for researching
independent sites, they are 61% versus 48%.
All EU (1848)
Face to face rep visit
Independent website (e.g. physician network)
Downloadable materials (e.g. documents, podcasts, webcasts)
Email from independent website (e.g. physician network)
Monograph
Email from pharmaceutical/device company
Product website
Slide deck
Pharmaceutical/medical device company website
Video
0.00 0.50 1.00 1.50
1.31
1.01
0.98
0.68
0.61
0.29
0.29
0.25
0.21
0.16
Downloadable content
0%
All respondents(n=1848)
20% 40% 60% 80%
Emails from independent websites
Independent websites
All choosing face to face rep visits as first choice(n=569)
All choosing face to face rep visits as one ofthree choices (n=1056)
All choosing NOTchoosing face to facerep visits as one ofthree choices (n=792)
50%
38%
41%
63%
34%21%
23%49%
48%
36%
39%61%
Figure 3: Preferences for receiving promotional material
Figure 3a: Use of independent sites analysed by propensity to see reps
HoW doCtors lIKe to reCeIve ProMotIonAl MAterIAl
How do doctors want to engage with pharma on new products? 05
When researching pharma products, doctors show a clear preference for scientific journals and independent websites, as shown in Figure 4. A massive 91% are keeping up with the latest science at least once a month.
the figure may well be higher if searching on the independent sites, which often post
a summary of the most important studies, is included. nearly three-quarters of all eu
doctors say they visit such sites weekly or monthly. the professional bodies come in a
close third as a source of information and these also cover the most pertinent research
in their area of medicine.
Concise information suits the busy working lives of doctors. Figure 4a shows the
top slots for usefulness of formats all go to summaries: of the medical guidelines,
of information on individual drugs, of medical protocols or algorithms, of single-
page rather than multiple-page details, and of clinical papers. For this question, the
doctors were asked to rank their answers from most to least useful where, in the data
processing, ‘most useful’ drew a score of 11 and ‘least useful’ a score of 1.
Figure 4: Frequency of information sources used
“Concise information suits the busy working lives of doctors”
PreFerred sourCes And ForMAts oF InForMAtIon
46%
100%
Scient
ific
jour
nals
Never
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Indep
enden
t
web
sites
Profe
ssion
al
bod
iesPha
rma
com
pany
Gover
nmen
t
body
Charit
y
Once a year
Once a month
Once a week
9%
45%
20%
42%
31%
27%
44%
22%
37%
7% 7% 9%
39%
15%
20%
37%
31%
13%
60%
46%
25%5%
Guideline summaries
Drug summary
Algorithms
Single page detail
Clinical paper summaries
Case reports
Mythbusters
Video content
Multiple page detail
Discussion with rep
Prescribing information
0.00 2.00 4.00 6.00 8.00
ALL EU (1848)
7.28
7.21
6.76
6.44
6.16
5.43
5.65
5.87
5.16
4.93
4.78
Figure 4a: Usefulness of information formats
HoW doCtors sPend tHeIr ProFessIonAl tIMe onlIne
06 How do doctors want to engage with pharma on new products?
european doctors spend a total of 21 hours a week online, 15.9 of which are for professional purposes, as shown in Figure 5. this average figure breaks down by country as follows:
• Germany: 16.5 hours online a week, 10.9 for professional purposes
• France: 16.1 hours online a week, 13 for professional purposes
• Italy: 24.7 hours online a week, 19.1 for professional purposes
• spain: 26.8 hours online a week, 21.8 for professional purposes
• uK: 22.2 hours online a week, 15.8 for professional purposes
While these figures do not relate to how doctors prefer to receive product
information, they do confirm that it should emanate from the web in some form
because, to all practical intents and purposes, this is where the medical profession
now works.
And the data is useful in other dimensions. It reveals, for example, that spanish
doctors spend more time than other europeans using prescribing software, clocking
up 12.7 hours a week. this is almost three times that of their German counterparts
who registered only 4.8 hours and just short of 50% more than the european
average figure of 8.6 hours a week. the spanish also use the internet more than
other europeans in terms of searching professional information and are second only
to Italy in terms of using it to stay in contact with other healthcare professionals.
30.0
25.0
20.0
15.0
10.0
5.0
0.0UK
(318)Spain(293)
Italy(266)
France(380)
Germany(332)
All EU(1848)
For social/non-professional purposes
For contacting other HCPsfor professional purposes
Information seeking forprofessional purposes
In your professional role to use prescribing software etc
6.4
2.5
4.1
9.212.7
6.4
2.7
5.0
5.6
2.8
6.0
7.3
7.3
3.8
1.9
3.1 5.6
1.8
4.3
4.8
8.6
5.0
2.3
5.1
Figure 5: Hours spent online by EU doctors per week
In terms of using the internet specifically to learn about medicine, the attitudes depicted in Figure 6 reveal a general consensus to keep up with new developments about drugs (1% in disagreement); that online information is easy and convenient to access (3% in disagreement) and that online resources are independent and objective (5% in disagreement). nevertheless, it is interesting to note that almost a third of doctors prefer contact with a rep to learn about a new drug as this offers more interaction.
How do doctors want to engage with pharma on new products? 07
AttItudes to onlIne leArnInG
I am interested in keeping up to datewith new developments about drugs
Online information is easyand convenient to access
I trust independent online resources asthey are independent and objective
I prefer contact with a rep for receiving drug info, as this offers more interaction
I would like to use online resources more but I need to be shown how
I participate in andcontribute to social networks
0% 20% 40% 60% 80% 100%
Agree
Neutral
Disagree
80% 19%
56% 40%
45% 50%
31% 52% 18%
20% 46% 34%
16% 45% 39%
Figure 6: Attitudes to online learning
“There’s a general consensus that … online information is easy and convenient to access.”
ConClusIons
european doctors have more confidence in pharma’s ability to improve the outlook for their patients than any measures to improve either patient management or patient education. they therefore have a strong interest in wanting to stay up-to-date on the latest pharma developments.
While pharma’s promotional material may not score well as a top influencer
of treatment, many doctors are open to receiving information via face-to-face
visits from sales reps, independent websites and downloadable content such as
documents, podcasts and webcasts.
How do doctors want to engage with pharma on new products? 08
ABout tHe AutHor
Dr Tim Ringrose, CEO, M3 (EU)
tim ringrose trained in nephrology and intensive care
in oxford before joining doctors.net.uk, part of M3,
in 2000. tim has led the development of services
provided to doctors and has had considerable
experience working with a wide variety of healthcare
clients to deliver market research, targeted online
communications and educational programmes to
doctors.
About M3 Group
M3 is a trusted global provider of information and
connections in healthcare, and has a reach of more
than 3.5m physicians worldwide - making it the world’s
largest network of physicians.
M3 helps healthcare organisations to access, connect
and communicate more effi ciently with physicians
and other healthcare professionals in order to share
knowledge and innovations. It also provides ongoing
data-driven results and insights, so that it can
continually improve its service.
For physicians, M3 provides dedicated and trusted
community spaces in which they can connect with each
other, as well as healthcare organisations - to learn,
access new information, and share knowledge and
experiences.
through its commitment to progress and its investment
in deepening connections, M3 will continue to
break down the barriers that stand in the way of
improvements and progress in healthcare.
Further information
For more information on M3 and its european division
which includes www.doctors.net.uk, www.mdlinx.com,
and www.networksinhealth.com
Phone: +44 (0)1235 828400
email: tim.ringrose@eu.m3.com
Website: http://eu.m3.com/
twitter: @M3_Europe
top related